ClinicalTrials.gg
CompletedNCT00714961CLARITY-TIMI28Updated Mar 25, 2009

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

A Phase 3 interventional study of Clopidogrel (SR25990) and Placebo in Acute Coronary Syndromes, sponsored by Sanofi. Completed at 24 sites in 24 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-03-25.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,491
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing clopidogrel in Acute Coronary Syndrome — 3 open to participants now, 3 under way, none of them phase 3. Clopidogrel · Acute Coronary Syndrome.

Enrollment
4th of 33
3,491 · median 200
Started
2003
the only one that year
Phase 3
8 of 34
none open now
Registered
4th of 34
by date

Among the 34 studies testing clopidogrel in Acute Coronary Syndrome, this one is the 4th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2003, is one of 8 in phase 3, and was the 4th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

3 of the 34 studies testing clopidogrel in Acute Coronary Syndrome are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing clopidogrel in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.

03

Conditions studied

  • Acute Coronary Syndromes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • STEMI within 12 hours of randomization
  • Planned treatment with a fibrinolytic agent and aspirin

Exclusion criteria

Exclusion Criteria:

  • Intention of performing coronary angiography within 48 hours of fibrinolysis
  • Treatment with clopidogrel or ticlopidine within 7 days prior to enrollment, or planned treatment with clopidogrel or ticlopidine.
  • to fibrinolysis
  • Planned use of a glycoprotein IIb/IIIa inhibitor
  • Prior CABG
  • Evidence of cardiogenic shock or acute pulmonary edema requiring intubation or an intraaortic balloon pump
  • Known renal or hepatic insufficiency
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,491 participants (actual)

Study arms

  • Experimental
    1

    Drug: Clopidogrel (SR25990)

  • Placebo comparator
    2

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. efficacy: composite of an included infarct-related artery on the pre-discharge angiogram, or death or recurrent MI by the time of the start of coronary angiography

  2. safety: TIMI major bleeding

Secondary outcomes

  1. Angiographic, clinical and electrocardiographic outcomes

07

Study locations

24 sites
  • Sanofi-Aventis
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis
    Buenos Aires, Argentina
  • Sanofi-Aventis
    Macquarie Park, Australia
  • sanofi-aventis Austria
    Vienna, Austria
  • sanofi-aventis Belgium
    Diegem, Belgium
  • sanofi-aventis Brazil
    Sao Paulo, Brazil
  • sanofi-aventis Canada
    Laval, Canada
  • sanofi-aventis France
    Paris, France
  • sanofi-aventis Germany
    Berlin, Germany
  • Sanofi-Aventis Hungaria
    Budapest, Hungary
  • Sanofi-Aventis
    Dublin, Ireland
  • Sanofi-Aventis
    Natanya, Israel
  • sanofi-aventis Italy
    Milano, Italy
  • Sanofi-Aventis Mexico
    Mexico, Mexico
  • sanofi-aventis Netherlands
    Gouda, Netherlands
  • sanofi-aventis Poland
    Warszawa, Poland
  • Sanofi-Aventis
    Porto, Portugal
  • Sanofi-Aventis
    Puerto Rico, Puerto Rico
  • Sanofi-Aventis
    Moscow, Russian Federation
  • sanofi-aventis South Africa
    Midrand, South Africa
  • sanofi-aventis Spain
    Barcelona, Spain
  • sanofi-aventis Sweden
    Bromma, Sweden
  • Sanofi-Aventis
    Istanbul, Turkey
  • sanofi-aventis UK
    Guildford, United Kingdom
08

References and documents

Publications

  • Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24;352(12):1179-89. doi: 10.1056/NEJMoa050522. Epub 2005 Mar 9. PubMed 15758000 ↗
  • Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BM. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan;159(1):55-62. doi: 10.1016/j.ahj.2009.10.033. PubMed 20102867 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Jan 2005 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2008
First posted
Jul 14, 2008
Start
Feb 2003
Primary completionActual
Jan 2005
CompletionActual
Jan 2005
Last update
Mar 25, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00714961
Lead sponsor
Sanofi
First posted
Jul 14, 2008
Start date
Feb 2003
Primary completion
Jan 2005
Completion
Jan 2005
Last update
Mar 25, 2009

Study contacts

Eugene Braunwald, MD
principal investigator · Brigham and Women's Hospital, Boston, MA, USA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion